StevenPLaRosaMD

PubMed

• 171 citations
  Phase 2 trial of eritoran tetrasodium (E5564), a toll-like receptor 4 antagonist, in patients with severe sepsis.
  Mark Tidswell, William Tillis, Steven P. LaRosa, Melvyn Lynn, AE Wittek
  Critical Care Medicine. 2010-01-01
• 571 citations
  Effect of eritoran, an antagonist of MD2-TLR4, on mortality in patients with severe sepsis: the ACCESS randomized trial.
  Steven M. Opal, Pierre-François Laterre, Bruno François, Steven P. LaRosa, Derek C. Angus
  JAMA. 2013-03-20
• 163 citations
  Long-Term Quality of Life Among Survivors of Severe Sepsis: Analyses of Two International Trials.
  Sachin Yende, Shamly Austin, Andrew Rhodes, Simon Finfer, Steven M. Opal
  Critical Care Medicine. 2016-08-01

Journal Articles

•  
  Bernard GR, Francois B, Mira JP,Vincent JL, Dellinger RP, Russell JA, et al., Crit Care Med, 1/1/2014
• Recombinant Human Activated Protein C as a Therapy for Severe Sepsis: Lessons Learned?  
  Opal SM, LaRosa SP, Am J Respir Crit Care Med, 1/1/2013
• A Randomized, Double-Blind, Placebo-Controlled, Phase-2B Study to Evaluate the Safety and Efficacy of Recombinant Human Soluble Thrombomodulin, ART-123, in Patients wi...  
  Vincent JL, Ramesh M, Ernest D, Crit Care Med, 1/1/2013
• A Controlled Clinical Trial of Eritoran, an Antagonist of MD2-TLR4, in Patients with Severe Sepsis: THE ACCESS TRIAL  
  Opal SM, Laterre PF, Francois B, et al., JAMA, 1/1/2013
• White paper: recommendations on the conduct of superiority and organism-specific clinical trials of antibacterial agents for the treatment of infections caused by drug...  
  LaRosa SP, Clin Infect Dis, 1/1/2012
• Immune Aspects of Sepsis and Hopes for new therapeutics  
  LaRosa SP, Opal SM, Curr Infect Dis Rep, 1/1/2012
• Real-Life Experience with Drotrecogin Alfa (Activated) for Severe Sepsis: An Effectiveness and Safety Meta-analysis and Meta-regression  
  Kalil AC, LaRosa SP, Lancet ID, 1/1/2012
• Therapies for Severe Sepsis Influence of Severity of Illness on the Effects of Eritoran Tetrasodium (E5564) and on Other Therapies for Severe Sepsis  
  Kalil AC, Gogate J, Lynn M, Opal SM; the Eritoran Sepsis Study Group, Shock, 1/1/2011
• Recombinant Tissue Factor Pathway Inhibitor in Severe Community-Acquired Pneumonia: A Randomized Trial  
  Wunderink RG, Laterre PF, François B, Perrotin D, Artigas A, Otero Vidal L, Lobo SM, San Juan J, Hwang SC, Dugernier T, et al., Am. J. Respir. Crit. Care Med, 1/1/2011
• Sepsis Strategies – Old and New  
  LaRosa SP, Opal SM, Clin Invest, 1/1/2011
• Phase 2 trial of eritoran tetrasodium (E5564), a TLR4 antagonist, in patients with severe sepsis  
  Tidswell M, Tillis W, et al., Crit Care Med, 1/1/2010
• Oseltamivir resistant 2009-2010 pandemic influenza A (H1N1) in an immunocompromised patient  
  Chan PA, Connell NT, Gabonay AM, Westley B, Larkin JM, et al., Clin Microbiol Infect, 1/1/2010
• Year in Review 2008: Critical care sepsis  
  Opal SM, LaRosa SP, Critical Care, 1/1/2009
• A clinical evaluation committee assessment of recombinant human tissue factor pathway inhibitor (Tifacogin) in patients with severe community-acquired pneumonia  
  Laterre PF, Opal SM, Abraham E, Creasey AA, Xie F, Poole L, Wunderink RG, Critical Care, 1/1/2009
• Diagnostic dilemma: The heart of the matter  
  Holubar M., Connor M., Singh A, Am J Med, 1/1/2009
• A case of undiagnosed syphilis in a patient undergoing coronary artery bypass graft and aortic valve surgery  
  Soliman MM, Dorotta I, et al., Infect Dis Clin Pract, 1/1/2008
• Drotrecogin alfa (activated) in severe sepsis[comment]  
  LaRosa SP, N Engl J Med, 1/1/2006
• Decreased protein C, protein S and antithrombin levels are predictive of poor outcome in gram-negative sepsis caused by Burkholderia pseudomallei  
  Opal SM, Utterback B, et al., Int J Infect Dis, 1/1/2006
• What’s new in antibiotics?  
  Padmanabhan R, Tomecki KJ, Dermatol Clin, 1/1/2005
• Clinical trials of novel anticoagulants for severe sepsis: A tale of three molecules  
  LaRosa SP, Opal SM, Adv Sepsis, 1/1/2004
• Antibiotics: What’s new  
  LaRosa SP, Tomecki KJ, Cutis, 1/1/2004
• The clinical evaluation committee in a large phase 3 trial of drotrecogin alfa (activated) in patients with severe sepsis (PROWESS)  
  Dhainaut JF, Laterre PF, et al., Crit Care Med, 1/1/2003
• Tick-borne infections  
  Singh-Behl D, Tomecki KJ, Dermatol Clin, 1/1/2003
• Should prophylaxis for pneumocystis carinii pneumonia in solid organ transplant ever be discontinued?  
  Gordon S, Kalmadi S, et al., Clin Infect Dis, 1/1/1999
• Join now to see all

Books/Book Chapters

• Cleveland Clinic Internal Medicine Case Reviews 
  Chapter: 59 year old diabetic man with a painful hand ulcer 
  Tabbarah K, Choueiri T, Tachopoulou O,Editors: Longworth DL, Stoller JK, Casey DM, Jewell JK.Lippincott, Williams and Wilkins, Philadelphia2003

Abstracts/Posters

• Removal of Cytomegalovirus from blood by Heparin-functional Hemoperfusion Media
  McCrea K, Ward R, 44th Critical Care Congress, Phoenix, AZ, 1/17/2015
• Real-Life Experience with Drotrecogin Alfa Activated for Severe Sepsis: An Effectiveness and Safety Meta-analysis
  Kalil AC, LaRosa SP, 40th Critical Care Congress, San Diego, CA, 1/15/2011
• Comparative Efficacy of Eritoran, a Toll-Like Receptor 4 Antagonist, in Patients with Severe Sepsis and Higher Risk of Mortality by Type of Causative Pathogen
  LaRosa SP, Tidswell MA, 40th Critical Care Congress, San Diego, CA, 1/15/2011
• Serum Procalcitonin and Prothrombin Fragment 1.2 in Severe CAP: Can Biomarkers Predict Survival Benefit in Tifacogin Patients?
  Opal S, Laterre PF, Wunderink R, Su G, Hua, Y, Mendelson M, 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)/46th Annual Meeting the Infectious Diseases Society of America, Washington, DC, 1/25/2008
• Therapeutic Rationale for Tissue Factor Pathway Inhibitor (TFPI) for Severe Community Acquired Pneumonia CAP)
  Opal S, Wunderink R, Laterre PF, Creasey AA, Tobias J, 42nd Annual Meeting of the Infectious Diseases Society of America, Boston, MA, 1/30/2004
• Fungal Infections as an Important Cause of Severe Sepsis
  Garber GE, Opal SM, Maki DG, Focus on Fungal Infections 13, Maui, HI, 1/19/2003
• A pilot study to examine the presence of Cytomegalovirus viremia and its relationship with adrenal function in patients with acute refractory septic shock
  Starkey C, Yen-Lieberman B, Annane D, Bellisant E, Crit Care Med, 1/1/2003
• Effect of Baseline Protein C, Antithrombin and IL-6 Levels on the Mortality Reduction Associated with Recombinant Human Activated Protein C in Patients with Severe Sepsis
  Dhainaut JF, Fisher CJ, Yan SB, Bernard GR for the PROWESS Study Group, American Thoracic Society International Conference, San Francisco, CA, 1/18/2001
• Effect of Age on the Mortality Reduction Associated with Recombinant Human Activated Protein C in Patients with Severe Sepsis
  Ely EW, Helterbrand JD, Bernard GR for the PROWESS Study Group, American Thoracic Society International Conference, San Francisco, CA, 1/18/2001
• Baseline Characteristics of Patients enrolled in the Phase III trial of rhAPC in Severe Sepsis
  Vincent JL, Bellomo R, et al., The Society of Critical Care Medicine’s 30th Critical Care Congress, 1/1/2001
• The Efficacy and safety of Recombinant Human Activated Protein C for the Treatment of Patients with Severe Sepsis
  Bernard GR, Laterre PF, et al., The Society of Critical Care Medicine’s 30th Critical Care Congress, 1/1/2001
• Drotrecogin Alfa (Activated) Reduces Mortality in Patients with Severe Sepsis Irrespective of Bacterial Pathogen Classification
  Basson B, Dhainaut JF, Kimasewitz G, Opal SM, 41st International Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, 1/1/2001
• Decreased Protein C, Protein S and Antithrombin III Levels are Predictive of Poor Outcome in Gram-negative Sepsis caused by Burkholderia pseudomallei
  Opal SM, Utterback B, Yan B, Helterbrand J, Simpson AJ, White N, Fisher CJ, Crit Care, 1/1/2000
• Purpura Fulminans and S. Pneumoniae Sepsis with Severe Acquired Protein C Deficiency Successfully Treated with Recombinant Human Activated Protein C
  Smith K, Neal J, Winton E, Fisher C, XVII Congress of the Intl. Society on Thrombosis and Haemostasis, Washington, DC, 1/1/1999
• Pneumocystis carinii Pneumonia in Patients without AIDS
  Kalmadi S, Longworth D, Truesdell L, Fisher C, Cornish N, Gordon S, 34th Annual Meeting of the Infectious Diseases Society of America; 35th Annual Meeting of the Infectious Diseases Society of America, New Orleans, LA, 1996; San Francisco, CA, 1997, 1/18/1997
• Should Prophylaxis for Pneumocystis carinii Pneumonia in Solid Organ Transplant Ever Be Discontinued?
  Gordon S, Kalmadi S, Truesdell L, Avery R, Arroliga A, Longworth D, 34th Annual Meeting of the Infectious Diseases Society of America, New Orleans, LA, 1/18/1996
• Join now to see all

Lectures

• A General Review of Procalcitonin and Utilization in De-escalating Antibiotics 
  Fatima Hospital, North Providence, RI - 1/6/2014
• Severe Sepsis 
  Beverly Hospital, Beverly, MA - 1/30/2013
• Procalcitonin: Pro/Con Debate 
  San Antonio, TX - 1/9/2012
• ACCESS Trial Results 
  Houston, TX - 1/6/2012
• Biomarkers for Sepsis: From Readily to Experimental 
  The Warren Alpert Medical School of Brown University, Providence, RI - 1/20/2011
• Antithrombotics for Sepsis 
  San Diego, CA - 1/18/2011
• The Sepsis Disease State 
  Scott and White Healthcare, Temple, TX - 1/5/2011
• The Future of Sepsis Clinical Research 
  Snyder Institute of Infection, Calgary, Canada - 1/5/2011
• Biomarkers for Sepsis 
  Miami, FL - 1/9/2010
• A 51-year-old female presents with fever and generalized fatigue 
  The Warren Alpert Medical School of Brown University, Providence, RI - 1/2/2010
• A 44-year-old woman with abdominal pain and lower extremity rash 
  The Warren Alpert Medical School of Brown University, Providence, RI - 1/22/2009
• C. Difficile 
  Rhode Island Hospital and the Miriam Hospital Division of Critical Care Medicine, Providence, RI - 1/17/2009
• Sepsis and Septic Shock 
  University of Rhode Island, Providence, RI - 1/16/2009
• Procalcitonin 
  The Warren Alpert Medical School of Brown University, Providence, RI - 1/25/2008
• Antibiotic Issues in the ICU 
  Rhode Island Hospital and the Miriam Hospital Division of Critical Care Medicine, Providence, RI - 1/6/2008
• A 56-year-old man with fever and recent travel 
  The Warren Alpert Medical School of Brown University, Providence, RI - 1/23/2007
• A 66-year-old man with six weeks of increasing abdominal girth 
  The Warren Alpert Medical School of Brown University, Providence, RI - 1/13/2007
• Purpura Fulminans 
  Cleveland, OH - 1/11/2007
• A 52-year-old man with fevers and chills 
  The Warren Alpert Medical School of Brown University, Providence, RI - 1/10/2007
• Sepsis, Severe Sepsis, and Septic Shock 
  Providence, RI - 1/9/2007
• TNF as a specific target in severe sepsis - Is the story over 
  The Warren Alpert Medical School of Brown University, Providence, RI - 1/29/2006
• Infections Related to Trauma 
  The Warren Alpert Medical School of Brown University, Providence, RI - 1/17/2006
• An 88-year-old man with CMML who presents with progressive weakness and fatigue 
  The Warren Alpert Medical School of Brown University, Providence, RI - 1/7/2006
• A 58-year-old man with chest pain radiation to his back and new onset lower extremity weakness 
  The Warren Alpert Medical School of Brown University, Providence, RI - 1/12/2005
• Current Management of Severe Sepsis and Septic Shock 
  The Warren Alpert Medical School of Brown University, Providence, RI - 1/12/2005
• Join now to see all

Other

• Sepsis 
  LaRosa SP, Opal SM, Scientific American Textbook of Medicine
  http://www.sciammedicine.com/sciammedicine/institutional/tableOfContent.action#
  1/1/2014